Drug Developer News Today

Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D., Pharm.D., Experienced Biotechnology Portfolio Manager, Appointed Chief Business...

ZURICH (Reuters) -Roche agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly. On top of the upfront purchase price of $2.7 billion, Carmot's equity holders will receive payments of up to $400 million if certain milestones are achieved, the Swiss drugmaker said in a statement on Monday. The takeover target's most promising drug candida...

(Bloomberg) -- Roche Holding AG agreed to pay as much as $3.1 billion for Carmot Therapeutics Inc., a developer of the new type of weight-loss treatments that’s sparked a pharma industry gold rush.Most Read from BloombergHow Suspects Laundered Billions in Singapore for YearsBonds Retreat as Doubts Over Rate Cuts Creep In: Markets WrapBitcoin Surges Past $42,000 as Crypto Rally Gathers SteamHere’s How to Invest in Gold as It Hits an All-Time HighAlaska Air Agrees to Buy Hawaiian in ...

The voucher, which is transferable, allows a drug developer to expedite the review process of its product even if it does not fit requirements for a quick process. This would be the third priority voucher sale for bluebird after selling two for a combined $197 million over the past one year. The FDA's decision is expected by Dec. 20 and the bluebird therapy could potentially be the second for the rare disease.

/PRNewswire/ -- The "SARM1 Inhibitors Market by Target Indications, Type of Molecules, Drug Developers, Drug Candidates and Key Geographies: Industry Trends...

The condition -- characterized by stinging, sensitivity to light, blurred vision and eye fatigue -- affects about 38 million Americans, and is currently treated with over-the-counter artificial tear drops such as GenTeal and Refresh. Prescription eye drops, such as Novartis' Xiidra, AbbVie Inc's Restasis and Sun Pharmaceutical's Cequa are also used to treat dry eye disease. Oyster Point said Tyrvaya, a twice daily nasal spray, was tested in a late-stage and two mid-stage trials...

If you want to build a career in the Indian clinical research industry, here are a few points you need to know.

Apart from Covishield, the Serum Institute of India (SII) is working on four more vaccines against the novel coronavirus, according to Suresh Jadhav, executive director at one of the worlds largest vaccine manufacturers. Jadhav informed during a webinar that the firm has been working on five vaccines against the novel coronavirus, including the Covishield which got approval for emergency use roll-out for mass immunization drive began on Saturday. "For one (vaccine) we have received emergency...

Drug developer and some womens groups. they are accusing the fda of gender bias and 257 other drugs out there to help men but they havent approved one for women. one drug has been rejected twice. its going to be reviewed again on thursday. a new treat for "50 shades of grey" fans. the author of the popular erotic novel announced her next book will be coming out next month. cant wait. this will be simply titled "grey." do what works. it tells a story from christian greys point of view. the author...